Barr Labs and Pliva: Round 2

So much for a nice, easy bid for Pliva. The Croatian generic drugmaker is now a hot property, as a previously spurned bidder, Icelandic generics firm Actavis, refuses to let Barr Labs (NYSE: BRL  ) win this battle yet.

Pliva management rejected Actavis' prior offers as inadequate, publicly endorsing Barr Labs instead. Since then, though, Actavis has not only tried to trump Barr Labs in price (offering $2.3 billion as opposed to Barr's original $2.2B offer), but has also been busy buying shares of Pliva in the market -- which antitrust law prohibits Barr from doing. As a result of these actions, Actavis owns nearly 10% of the shares outright and has call options on nearly another 11%.

By the same token, Barr Labs isn't giving up without a fight. It's matched the Actavis offer, and it retains a slight advantage as the Pliva board's original buyer of choice. What's more, given Pliva's valuation, Barr can probably afford to raise its price a bit more but still get decent value for its money.

This story just keeps getting weirder. In conjunction with its raised offer, Actavis stated that its bid was superior because it wasn't facing a U.S. or German antitrust review, as the Barr Labs bid must. Perhaps this was a mistranslation or misunderstanding; Actavis may have meant that its deal wasn't contingent upon securing such approval. Let me tell you, if Actavis thinks it can just ram the deal past U.S. and German regulators, it's in for a nasty shock.

Whoever Pliva lands with, it will become part of the third-largest generics company in the world. It won't send the likes of Teva (Nasdaq: TEVA  ) or Novartis' (NYSE: NVS  ) Sandoz unit screaming in fear, but the combined firm will nevertheless become a notable player.

Stay tuned. I'm betting that Barr Labs still wins the battle, but it could prove to be a much longer war.

Further generic Foolishness:

To discover which pharmaceutical powerhouses also dish out potent dividends, subscribe toMotley Fool Income Investor. You'll get full access to all of Mathew Emmert's market-beating picks with a free 30-day guest pass.

Fool contributor Stephen Simpson has no financial interest in any stocks mentioned (that means he's neither long nor short the shares).


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 514405, ~/Articles/ArticleHandler.aspx, 9/2/2014 7:43:21 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement